Dr. Anna Sebestyén is a senior research fellow and the leader of Tumor
Biology and the Tumor Metabolism Research Group, as well as the director of the
institutional Tissue and Cell Culture Laboratory of the 1st Department of
Pathology and Experimental Cancer Research at Semmelweis University Faculty of
Medicine in Budapest, Hungary. She obtained her Ph.D. in Pathology-Oncology
from Semmelweis University. During her university studies, she joined Professor
Laszlo Kopper’s research group at Semmelweis University in investigating apoptosis
in lymphoma and altered signaling mechanisms in cancer. She and her research
team made significant contributions to the pathological characterization of
signaling failures and deregulated mTOR in malignancies. Her current research
interest is the investigation of the alteration of tumor mTOR activity and its
signaling background and its relevance in tumor biology, including the effects
of two different mTOR complexes on the metabolic adaptation of tumor cells. She
is the recipient of several teaching and scientific research awards from the
prestigious Hungarian Academy of Sciences and Semmelweis and Eötvös Loránd
Universities. She also serves on the editorial board of Pathology and Oncology
Research as assistant chief editor and Frontiers in Oncology as associate
editor of the Cancer Metabolism Section.
Research Keywords & Expertise
Cancer
Metabolism
mTOR signaling pathway
Tumour heterogeneity
Signalling networks
Short Biography
Dr. Anna Sebestyén is a senior research fellow and the leader of Tumor
Biology and the Tumor Metabolism Research Group, as well as the director of the
institutional Tissue and Cell Culture Laboratory of the 1st Department of
Pathology and Experimental Cancer Research at Semmelweis University Faculty of
Medicine in Budapest, Hungary. She obtained her Ph.D. in Pathology-Oncology
from Semmelweis University. During her university studies, she joined Professor
Laszlo Kopper’s research group at Semmelweis University in investigating apoptosis
in lymphoma and altered signaling mechanisms in cancer. She and her research
team made significant contributions to the pathological characterization of
signaling failures and deregulated mTOR in malignancies. Her current research
interest is the investigation of the alteration of tumor mTOR activity and its
signaling background and its relevance in tumor biology, including the effects
of two different mTOR complexes on the metabolic adaptation of tumor cells. She
is the recipient of several teaching and scientific research awards from the
prestigious Hungarian Academy of Sciences and Semmelweis and Eötvös Loránd
Universities. She also serves on the editorial board of Pathology and Oncology
Research as assistant chief editor and Frontiers in Oncology as associate
editor of the Cancer Metabolism Section.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
